Abstract:Objective:To evaluate the ability of vascular endothelial growth factor receptor 2(VEGFR2)/integrin α vβ 3 dual-targeted microubble (MBD) to target angiogenesis of renal cell carcinoma (RCC) in vivo. Methods:Non-targeted microbubble (MBN) USphere LA was employed as a template to prepare single- and dual-targeted microbubbles which could bind VEGFR2 and/or integrin α vβ 3 (MBV and MBI) by the biotin-avidin bridging method. A total of 40 RCC nude mice models were established by subcutaneously injecting 786-O cells.Twenty of the models were all injected with MBN, MBV, MBI and MBD in a random order, and the other 20 models were registered for antibody blocking assays. The results of ultrasound images were used for quantitative analyses, and the following quantitative parameters were obtained: intensity increment (a 1), peak halving speed (a 2), curve rising slope (a 3), perfusion time (t 0), time to peak (TTP), peak intensity (PI), mean transit time (MTT) and area under the curve (AUC) for the first three minutes, peak intensity at 10 s before (P 1) and after (P 2) ultrasound destruction, and the differences of tissue enhancement (dTE) between P 1 and P 2 (dTE=P 1-P 2). All the quantitative parameters of four contrast agents and the antibody blocking assays were compared.Besides, the immunohistochemical assays were performed to evaluate the expression of CD31, VEGFR2 and integrin α vβ 3 in tumor tissues. Results:The differences of parameters of a 1, a 3, t 0, TTP, PI and P 2 among four different microbubbles had no statistical significances (all P>0.05), and all parameters between the two single-targeted contrast agents were not statistically different (all P>0.05). The parameters of AUC, MTT, P 1 and dTE all showed a trend that dual-targeted bubbles > single-targeted bubbles > non-targeted bubbles (all P<0.05). On the contrary, the trend of dual-targeted bubbles < single-targeted bubbles < non-targeted bubbles (all P<0.05) was observed for a 2. In the antibody blocking experiment, a 2 was faster after the antibody injection ( P<0.001), while AUC, MTT, P 1 and dTE were all lower than those before the antibody injection ( P<0.001), and the other parameters were not statistically different before and after the antibody injection (all P>0.05). Immunohistochemical analyses confirmed the high expression of CD31, VEGFR2 and integrin β 3 in tumor tissues. Conclusions:The VEGFR2 and integrin α vβ 3 dual-targeted microbubble has a good potential to target the angiogenesis of human RCC in vivo.

Characteristics of VEGFR2-targeted Lipid Microbubbles Contrast-Enhanced Ultrasound in Nude Mice with Subcutaneous Colonic Carcinoma Xenografts: Compared with Lipid Microbubbles

Study on the Therapeutic Efficacy of Subcutaneous Colon Cancer Xenograft Tumor with Ultrasound Destruction of VEGFI-carrying Microbubbles

Study on Hypovascular Tumor' S Treatment with Targeted Mierobubbles Combined with Ultrasonic Abrupted Destroy

Molecular ultrasound imaging with vascular endothelial growth factor receptor 2-targeted microbubbles in a mouse liver cancer model

An Experimental Research into Endostatin Microbubble Combined with Focused Ultrasound for Anti-Tumor Angiogenesis in Colon Cancer

Targeted Contrast-Enhanced Ultrasound in the Assessment of Renal Cell Carcinoma Angiogenesis in Nude Mice

Anti-tumor Efficacy of Ultrasonic Cavitation is Potentiated by Concurrent Delivery of Anti-Angiogenic Drug in Colon Cancer

A novel therapeutic strategy using ultrasound mediated microbubbles destruction to treat colon cancer in a mouse model.

Effect of contrast-enhanced ultrasound imaging of VEGFR2 targeted microbubbles in murine renal tumor model

Study on the Therapeutic Efficacy of Subcutaneous Pancreatic Cancer Xenograft Tumor with Ultrasound Destruction of Different Size Microbubbles

Contrast-enhanced ultrasound imaging and quantitative parameters of fluorocarbon:compared with SonoVue

Preparation of vascular endothelial growth factor receptor 2-targeted ultrasonic contrast agent and its ability oftargeting tumor cellsin vitro

Passive Targeting Study of Nanoscale Lipid Ultrasound Contrast Agents on Tumors

Evaluation of a Targeted Nanobubble Ultrasound Contrast Agent for Potential Tumor Imaging

Experimental study of vascular endothelial growth factor receptor 2 and integrin α vβ 3 dual-targeted microbubble to assess tumor angiogenesis of renal cell carcinoma in vivo

Quantitative assessment of intratumoral microvascular perfusion in a nude murine hepatocellular carcinoma model:Preliminary study with contrast-enhanced ultrasonography

Development and Evaluation of A Novel Vegfr2-Targeted Nanoscale Ultrasound Contrast Agents

Dual-Targeted Microbubbles Specific to Integrin Αvβ3 and Vascular Endothelial Growth Factor Receptor 2 for Ultrasonography Evaluation of Tumor Angiogenesis.

[Microbubbles enhanced HIFU ablation on rabbit hepatic VX2 tumors: detecting residual tumor with contrast-enhanced ultrasound and spiral CT].

Diagnostic Ultrasound and Contrast Microbubbles on New Capillaries

Feasibility of Using 3D Contrast Enhanced Ultrasound Technology to Predict the Treatment Effect of Targeted Drugs-Loaded Thermosensitive Hydrogel Therapy on the Rabbit Vx2 Tumor Model